Bristol/Celgene A Record-Setting Merger, If It Happens
Executive Summary
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
You may also be interested in...
BMS’s Mezigdomide Myeloma Data Give Glimpse Of CELMoD Future
The trial’s principal investigator said the goal is to establish mezigdomide for use in patients who have failed on Pomalyst. BMS is running a head-to-head trial of both drugs.
J.P. Morgan Stockwatch: No Substitute For M&A
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
As Expected: Shareholders Back Bristol's $74bn Celgene Buy
With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.